Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra®...
MeningitisMeningococcal InfectionThe study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02. In addition, the kinetics of the antibody response will be evaluated in a subset of participants who will receive a booster dose of Menactra® vaccine and children in the same age group not previously vaccinated with a meningococcal vaccine or had meningitis disease who will receive a dose of Menactra® vaccine.
Kinetics of B Cell Response in Infants Menjugate Vaccination
Prevention of Meningococcal InfectionKinetics of B cell response in infants Menjugate vaccination
Can we Reduce the Number of Vaccine Injections for Children?
Invasive Meningococcal DiseaseThis open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccines in infancy. 498 infants will be enrolled in this multi-centre trial. Participants will receive either 0, 1, or 2 priming doses of a MenC-CRM197 conjugate vaccine or 1 priming dose of a MenC-TT conjugate vaccine in the first year of life, with all groups receiving a dose of a combination Hib-MenC-TT vaccine at 12 months, as well as all other concurrent routine vaccinations. All groups will also be further divided into 2 groups to receive their routine vaccines in either consistent or alternating limbs to assess the immune response to the concurrent infant routine immunisations administered in consistent versus alternating limbs. Immune responses will be assessed at 5, 12, 12months +6 days, 13 and 24 months of age.
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612...
InfectionsMeningococcalSubjects were previously vaccinated at 11 to 17 years of age. This extension phase starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension phase. No new subjects will be enrolled.
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
Meningococcal DiseaseThe purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.
Persistence of Immune Response After Vaccination With MCC
Prevention of Meningococcal InfectionPersistence of Immune response after vaccination with MCC
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course...
Meningococcal DiseaseMeningococcal MeningitisThis was a Phase 2b/3, multi-center, extension study of V72P10 to assess antibody persistence at 18 months after the vaccination course in study V72P10 (NCT00661713). Subjects who participated in study V72P10, and who meet all other enrollment criteria for this extension study, and a group of naïve subjects (defined as subjects who had never received rMenB+OMV NZ or other experimental MenB vaccines) of similar age to the subjects who were eligible to participate in this extension study, performed one study visit in which a single blood sample was drawn for MenB serological analyses.
Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination...
Prevention of Meningococcal InfectionPersistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine
Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal...
Pneumococcal InfectionsMeningococcal InfectionsThe purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningococcal conjugate vaccine given at either two and three or two and four months of age.
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra®...
MeningitisMeningococcal InfectionThe study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 15 to 23 years (not yet 24 years) who had been vaccinated five years previously in Study MTA02 and did not participate in Study MTA19 (NCT 00777790). In addition, the kinetics of the antibody response will be evaluated in a subset of these participants who will receive a booster dose of Menactra® vaccine. This will be compared to aged matched control subjects who have not been previously vaccinated with a meningococcal vaccine or had documented meningitis disease who will also receive a dose of Menactra® vaccine.